Vmbook Online ordering

Poniard Pharmaceuticals Inc

Poniard Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of innovative drugs for cancer and other diseases. The company's stock symbol is PARD, and it is listed on the NASDAQ stock exchange.

Here are some key facts about Poniard Pharmaceuticals, Inc.:

1. Headquarters: South San Francisco, California, USA

2. Focus: Oncology and other disease therapies

3. Products:

* Poniard's lead product candidate is picoplatin, which is in Phase 2 clinical trials for the treatment of small cell lung cancer and platinum-resistant ovarian cancer.

* Other pipeline candidates include PARD002 for HER2-positive breast cancer and PARD917 for cancer and immuno-oncology applications.

4. Financials:

* Poniard Pharmaceuticals has a market capitalization of around $200 million (as of March 2023).

* The company's stock price has experienced significant fluctuations due to clinical trial results, regulatory updates, and market sentiment.

* As of March 2023, the stock price is around $4.50 per share, with a 52-week range of $3.20 to $8.80.

5. Earnings and Growth:

* The company's revenue has been primarily from collaboration agreements and government grants, totaling around $11 million in 2022.

* Poniard Pharmaceuticals has been investing heavily in research and development (R&D), with expenses amounting to $17.3 million in 2022.

* The net loss for 2022 was $24.5 million, or $0.32 per share.

6. Industry Comparison:

* Poniard Pharmaceuticals operates in the biotechnology industry, which is highly competitive and reliant on successful drug development and regulatory approvals.

* Comparable companies in the biotechnology space include those focused on cancer therapies, such as Clovis Oncology, Acerta Pharma, and ImmunoGen.

7. Key Developments:

* In November 2022, Poniard Pharmaceuticals announced that its Phase 2 clinical trial for picoplatin in small cell lung cancer did not meet its primary endpoint. This led to a significant decline in the company's stock price.

* The company has since announced plans to explore strategic alternatives, including partnerships, collaborations, or a potential sale of the company.

Investors and analysts follow Poniard Pharmaceuticals' progress closely, focusing on the success of its clinical trials, regulatory approvals, and potential partnerships or acquisitions. The company's future success largely depends on the development and commercialization of its product candidates, particularly picoplatin, and its ability to secure partnerships or collaborations to advance its pipeline.